secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2024-12-04T23:59:59+00:00
Accession:  0001213900-24-105245
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Phase 3 Reliance II trial for REL-1017 in MDD deemed futile at interim analysis
--------------------------------------------------------------------------------

- DMC interim analysis indicates Reliance II is futile, unlikely to meet primary efficacy endpoint with statistical significance.
- No new safety signals reported; DMC did not identify any safety concerns.
- Relmada to evaluate next steps for REL-1017 program; continues development of REL-P11 for metabolic disease.
- Cash and cash equivalents ~$54.1M as of Sep 30, 2024, providing runway.
- Sergio Traversa, CEO, expressed disappointment and gratitude to participants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390024105245/0001213900-24-105245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390024105245/ea0223563-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-105245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer